ArticleClinical drug investigation2019

Open-Label Study to Assess the Efficacy of Ipragliflozin for Reducing Insulin Dose in Patients with Type 2 Diabetes Mellitus Receiving Insulin Therapy.

Hisamitsu Ishihara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.